Constitutive proteasomes and immunoproteasomes shape the peptide repertoire presented by major histocompatibility complex class I (MHC-I) molecules by harboring different sets of catalytically active subunits. Here, we present the crystal structures of constitutive proteasomes and immunoproteasomes from mouse in the presence and absence of the epoxyketone inhibitor PR-957 (ONX 0914) at 2.9 Å resolution. Based on our X-ray data, we propose a unique catalytic feature for the immunoproteasome subunit b5i/LMP7. Comparison of ligand-free and ligand-bound proteasomes reveals conformational changes in the S1 pocket of b5c/X but not b5i, thereby explaining the selectivity of PR-957 for b5i. Time-resolved structures of yeast proteasome:PR-957 complexes indicate that ligand docking to the active site occurs only via the reactive head group and the P1 side chain. Together, our results support structure-guided design of inhibitory lead structures selective for immunoproteasomes that are linked to cytokine production and diseases like cancer and autoimmune disorders.
INTRODUCTION
Nucleated cells of most vertebrates utilize MHC-I molecules to present peptides to the cell surface. These peptides may be derived from intracellular self-proteins or have foreign viral or bacterial origin, but all are products of protein degradation by the 20S proteasome core particle (CP) (Grant et al., 1995; Hershko and Ciechanover, 1998; Michalek et al., 1993; Townsend et al., 1988) . When a cytotoxic T cell binds to an immunogenic foreign peptide, embedded in the groove of MHC-I molecules, it is activated to kill the infected antigen-presenting cell (Rock and Goldberg, 1999) . The T cell subsequently releases cytokines, particularly tumor necrosis factor-a and interferon-g, that induce the expression of three specialized, catalytically active proteasomal b-subunits, designated b1i/LMP2, b2i/ MECL-1, and b5i/LMP7 (Aki et al., 1994; Brown et al., 1991; Glynne et al., 1991; Groettrup et al., 1996; Kelly et al., 1991; Martinez and Monaco, 1991; Nandi et al., 1996) . These immunoproteasome subunits (i-subunits) cooperatively assemble into nascent CPs, effectively substituting their constitutive counterparts (c-subunits) b1c/Y, b2c/Z, and b5c/X, respectively. Consequently, the de novo synthesis of CPs in inflamed tissues is largely in the form of immunoproteasomes (iCPs) (Griffin et al., 1998; Kingsbury et al., 2000) . Whereas iCP expression is inducible in most tissues, it is constitutive in hematopoetic cells, especially lymphocytes and monocytes. Moreover, in cortical thymic epithelial cells, a third class of mammalian proteasome, the socalled thymoproteasome (tCP), is expressed, which bears the subunit b5t and is involved in the positive selection of developing T cells (Murata et al., 2007) .
As a result of their different subunit compositions, constitutive proteasomes (cCPs), iCPs, and tCPs are endowed with different cleavage specificities; for example, iCPs preferentially hydrolyze proteins after nonpolar amino acids . The peptides produced by iCPs further stimulate the immune system, as their hydrophobic C termini are perfect anchor motifs for binding to MHC-I molecules (Romero et al., 1991) . However, it has been shown in gene-targeted mice that the i-subunits are not essential for epitope presentation in general, implying that the cCP is also to a considerable extent competent in antigen processing (Van den Eynde and Morel, 2001; Yewdell et al., 1994) .
Recent studies reported that b5i plays a pivotal role in cytokine production, and that small-molecule inhibitors of this subunit have therapeutic activity in mouse models of autoimmune diseases and inflammatory disorders Ichikawa et al., 2011; Muchamuel et al., 2009) . Thus, selective inhibition of the iCP subunit b5i represents a promising therapeutic alternative to the approved proteasome inhibitor bortezomib, 
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Residue numbers are assigned according to the sequence alignment to the b-subunit of T. acidophilum. Amino acid insertions compared to the sequence of T. acidophilum are designated by additional lowercase letters. Secondary structures (S: b sheet; H: helix) are indicated for the i-subunits. Structurally distorted amino acids are shown in gray, whereas residues important for the active site are displayed in red. Residues contributing to the substrate-specificity pockets are highlighted by colored boxes: S1 pocket, green; S2 pocket, blue; S3 pocket, brown; S 0 , yellow. Amino acid 113 is absent in all b1i-subunits (purple box). The which often causes neurotoxicity (Badros et al., 2007) . Currently, the irreversibly acting epoxyketone PR-957 is the most potent b5i-selective inhibitor (Muchamuel et al., 2009 ), but the molecular basis for its selectivity has remained elusive up to now. Here, we examine the murine cCP and iCP at the molecular level and provide structural explanations for the enhanced MHC-I antigen generation by iCPs. Moreover, X-ray structures of the mouse cCP and iCP as well as the CP from Saccharomyces cerevisiae (yCP) in the presence and absence of PR-957 (ONX 0914) revealed the basis for the b5i selectivity of this compound.
RESULTS

Elucidation of iCP, cCP, and yCP Crystal Structures in Complex with PR-957
Preparations of iCPs were isolated from livers of BALB/c mice 8 days after infection with lymphocytic choriomeningitis virus (LCMV), and cCPs were purified from livers of uninfected b2i À/À b5i À/À gene-targeted mice (Khan et al., 2001; Schmidtke et al., 2000) . After assessment of their purity by two-dimensional gel electrophoresis ( Figure S1 available online), both proteins were crystallized from conditions containing 2,4-methyl-pentanediol (MPD). Diffraction data of native crystals and crystals soaked with the epoxyketone inhibitor PR-957 were recorded to a maximum resolution of 2.9 Å . Data evaluation with the coordinates of the bovine cCP (Protein Data Bank [PDB] ID 1IRU; Unno et al., 2002) was followed by positional refinement as well as model building using 4-fold and 2-fold noncrystallographic symmetry (NCS) averaging for cCP and iCP, respectively. Electron density maps proved that each subunit was well defined and that all catalytically active sites of both cCP and iCP showed full occupancy of PR-957. Positive and negative F o -F c maps clearly depicted expected sequence changes from c-to i-subunits, allowing us to assign amino acid side chains unambiguously (Figure 2 ). Residue numbers were allocated on the basis of the alignment to the b-subunit of Thermoplasma acidophilum ( Figure 1 and Data S1) (Lö we et al., 1995) . All models were completed with final R free values below 27.5% and root-mean-square deviation (rmsd) bond and angle values of lower than 0.005 Å and 0.93 (Table S1 ). To explore the docking and the two-step reaction mechanism of epoxyketones, yCP crystals were soaked with two different concentrations of PR-957, and X-ray data were evaluated as previously reported (Groll and Huber, 2005) (Table S2) .
Architecture of the iCP
The quaternary structures of the cCP and iCP differ only in the substitution of the c-subunits b1c, b2c, and b5c by their i-counterparts b1i, b2i, and b5i ( Figure 3A) . The entry gates to the central proteolytic chambers are closed by the N termini of the a-subunits, and superposition of the a-rings from cCP and iCP reveals high structural similarity (rmsd C a-rings < 0.59 Å ) (Figure S2) . Thus, we speculate that regulation of the gating mechanism by activator complexes such as 19S, 11S (PA28), and PA200 is similar in cCPs and iCPs.
Structural superposition of identical a-subunits and inactive b-subunits from both proteasome types shows an rmsd of <0.35 Å for the C a backbone. Remarkably, the main chain tracings of exchangeable c-and i-b-subunits also match almost perfectly (rmsd < 0.72 Å ) ( Figure 3B ), despite the differences in their primary structures (sequence identity of b1c/b1i: 63.3%; b2c/b2i: 58.9%; b5c/b5i: 72.4%).
Most amino acid substitutions between murine c-and i-subunits are surface exposed, and comparison of the primary sequences of all known c-and i-subunits reveals that only a few substitutions occur in all species (b1i: 13.6%; b2i: 5.1%; b5i: 9.8%; Data S1B, S1D, and S1F). Moreover, the number of interactions that create contact surfaces between neighboring subunits varies from cCP to iCP (Table S3 ), but their influence on the overall stability of the complexes cannot be clarified from a structural point of view.
Insights into the Substrate-Binding Channels of the c-and i-Subunits Substrate affinities toward proteasome active sites are solely determined by enthalpic interactions with the primed and unprimed substrate-binding channels ( Figure 3C ). Whereas subunits b2i and b2c are identical with respect to their primed pockets, subunit b1i is shortened by one residue in the region 113-124 compared to b1c (Figure 2A ). This deletion is consistent among all b1i-subunits sequenced thus far and represents a hallmark feature that changes the possible contact sites for bound substrates. Similarly, the substitutions S115D and E116N in subunit b5i may affect cleavage preferences, but these residues are not conserved among species.
Compared to the primed pockets, the unprimed substratebinding channels are far better characterized and can be subdivided in S1, S2, and S3 specificity sites ( Figure 3C ). Subunit b2i is the only i-subunit that is not encoded on the MHC cluster; interestingly, its substrate-binding channel was found to be identical with that of b2c, except for the substitution of Asp53 (b2c) with Glu (b2i). Furthermore, no differences were observed in the ligand-free and ligand-bound states ( Figures S3A-S3D) . Thus, the rationale for the incorporation of subunit b2i into the iCP remains elusive, and b2-subunits may play an additional functional role that has yet to be described.
In contrast to the consistent character of subunits b2c and b2i, several important distinctions were observed upon comparison of b1c and b1i. The conserved substitutions T20V, T31F, R45L, and T52A in b1i increase the hydrophobicity of the S1 pocket and diminish it in size ( Figure S3E ). Consequently, peptide bond hydrolysis preferentially occurs after small, hydrophobic, and branched residues and more epitopes with nonpolar C termini, such as Ile, Leu, or Val, are generated for the presentation on MHC-I molecules (Cardozo and Kohanski, 1998; Orlowski et al., 1993; Romero et al., 1991) . This agrees with the specific cleavage of the fluorogenic model substrate Ac-PAL-AMC (Acetate-Pro-Ala-Leu-7-aminomethylcoumarin) by b1i (Blackburn et al., 2010) . Apart from the S1 pocket, the amino acid substitutions T22A and A27V in b1i, as well as Y114H in the adjacent b2i-subunit, collectively shape, downsize, and polarize the S3 site of the b1i entity ( Figure S3E ).
In the S1 pockets of the subunits b5c and b5i, the residues that give rise to chymotrypsin-like (ChTL) activity, Ala20, Met45, Ala49, and Cys52, are unchanged. Only amino acid 31 is variable in size but conserved in its hydrophobic character ( Figure S3I and Data S1F). In contrast to b5c-subunits, all known b5i entities harbor a shallow S2 pocket in position 48 formed by Cys or Ser. The substitution of Ala27 (b5c) by Ser (b5i) restricts the size of the S3 pocket of murine and human b5i and endows it with a more hydrophilic character compared to subunit b5c ( Figure S3I ).
In addition to these amino acid changes, the S1 pockets of b5c and b5i vary in their size. Distinct conformations of Met45 result in a spacious S1 pocket in b5i and a significantly smaller one in b5c ( Figure S3I ). Formation of a large S1 pocket, similar to chymotrypsin, is favored by strong van der Waals The electron densities (i-subunits: blue; c-subunits: red) represent 2F o -F c maps, with the displayed amino acids omitted for phasing. Contouring at even 0.8 s clearly depicts prominent amino acid exchanges, excluding a mixture of cCPs and iCPs. Predominantly, exchanges of bulky residues in the cCP by smaller side chains in the iCP are shown. (A) Superposition of the murine subunits b1i (green) and b1c (gray). The lack of amino acid 113 in the b1i-subunit results in shortening of the loop segment between Tyr111 and Arg121. (B) Superposition of the interface of subunits b2i/b1i and b2c/b1c analogous to (A). The electron density shows amino acid exchanges, namely Y25A in subunit b1i (green) and S131Q, L132G, as well as M135V in subunit b2i (brown). (C) Superposition of the murine subunits b5i (yellow) and b5c (gray) visualizes that Tyr88 is replaced by Leu in b5i. See also Figure S1 .
interactions of Met45 with the aliphatic side chain of Gln53. Whereas Gln53 is conserved in b5i-subunits, it is replaced in b5c-subunits by Ser, which cannot stabilize Met45 by hydrophobic interactions. As a result, b5c harbors a much smaller S1 pocket and thereby resembles elastase-like activity rather than ChTL activity. In addition, residue Lys32 (b5c)/ Asn32 (b5i) may also be crucial for the distinct architecture of the S1 pocket in b5c and b5i.
Although the yCP contains Gln53 in yb5, its interaction with Met45 is less dominant than in b5i; hence, Met45 adopts the same conformation as observed in b5c. From a structural perspective, yb5 represents a chimera between b5c and b5i, as for example Lys32 is conserved in b5c-subunits and Gln53 in b5i entities.
Unique Active Site Architecture of Subunit b5i
The hydrophilicity surrounding the active site nucleophilic Thr1O g and the oxyanion hole of subunit b5i is increased by the strictly conserved amino acid exchanges A46S and V127T. This elevated polarity might favor peptide bond hydrolysis by attracting water molecules. Moreover, the electron density displays a unique hydrogen bond network involving Gly47NH, as well as Ser46O g and Thr127O g ( Figures 4C, 4E , and S3I).
Because Ser46O g is directly hydrogen bridged to the oxyanion hole Gly47NH (3.1 Å ), it may contribute to the stabilization of the tetrahedral transition state during catalysis. This molecular feature is unique to b5i and could kinetically favor its proteolytic activity.
Molecular Basis for the Selectivity of PR-957 for Subunit b5i
In contrast to prominent proteasome inhibitors such as bortezomib, approved for the treatment of multiple myeloma and equally targeting the active sites of both b5c and b5i, PR-957 preferentially inhibits subunit b5i of iCPs (Muchamuel et al., 2009) (Figures 4A, 5, and S4) . However, elucidation of the molecular basis for the selectivity of PR-957 requires the structural comparison of its binding to all active c-and i-subunits. Using inhibitor concentrations in the mM range for crystal soaking experiments, PR-957 targeted all active sites of the iCP and cCP (Muchamuel et al., 2009 ) as well as yCP and, by covalently binding in each case, proved that all three distinct catalytic centers are active in the crystals. Notably, although subunit b7 was suggested to harbor an active site in the bovine cCP apo-crystal structure (Unno et al., 2002) , it was not occupied by PR-957 in the cCP and iCP. The electron density maps display that the C-terminal dipeptide of PR-957 forms an antiparallel b sheet in each substratebinding channel ( Figure 4B ), whereas the N-terminal morpholine moiety is not engaged in any interactions with the protein (Figures S5A-S5I ). In all b2-and b5-subunits, the N-terminal peptide bond of the inhibitor is further stabilized by a hydrogen bond involving residue Asp114 of subunits b3 and b6 ( Figures  S5A-S5C and S5G-S5I).
All b2-subunits harbor very spacious S1 pockets that cannot sufficiently stabilize PR-957 in the substrate-binding channel and disfavor ligand binding compared to b5i for energetic reasons ( Figures S3A-S3D and S5A-S5C). In contrast, binding of PR-957 to b1c is hampered due to steric hindrance by Arg45, which has to be dislocated to enable covalent modification of Thr1. Additionally, the hydrophilic S1 pocket of subunit b1c opposes binding of the hydrophobic P1 residue of PR-957. Although the hydrophobicity of the substrate-specificity pockets of b1i supports PR-957 binding, atomic distances indicate that Phe31 creates a steric barrier to the P1 phenyl moiety of . Hence, the inhibitor might bind only against significant repulsive forces mirrored in an unfavorable orientation of Phe31 toward the carbonyl oxygen of Asp32 (b1i).
To complement the crystal structures, the IC 50 values of PR-957 for the ChTL activity of various CPs were determined ( Figure 5 ). Inhibitory activity against murine, human, and yeast b5c-subunits was observed in the micromolar range (IC 50 for mb5c: 0.92 mM; hb5c: 1.0 mM; yb5: 0.55 mM). In contrast, b5i from mice and humans displayed IC 50 values in the nanomolar range, in agreement with previous studies (mb5i: 65 nM; hb5i: 73 nM) (Muchamuel et al., 2009 ). To investigate this phenomenon, b5i-subunits were compared in the ligand-free and ligand-bound states, showing almost identical substrate-binding channels. Only minor structural reorientations of the CH 3 -S-group of Met45, forming the bottom of the S1-specificity pocket, and Met31 are required to avoid clashing with the P1 phenylalanine of PR-957 (rmsd C a b5i/b5i:PR-957: 0.28 Å ) ( Figures 4C, 6A, and 6B) . However, superposition of b5c alone and in complex with PR-957 reveals that rotation of the whole side chain of Met45 is required for binding of PR-957 ( Figures 4D, 6C, and 6D ). This structural rearrangement in the S1-specificity pocket causes the reorientation of Ile35 and triggers further major conformational changes involving residues 34 to 76. Thus, PR-957 binding to the cCP results in the offset of the b sheets S4 and S5 as well as a helix H1 by up to 1.7 Å (rmsd C a b5c/b5c:PR-957: 0.64 Å ). Although superposition of the ligand-bound subunits b5c and b5i indicates structural similarity (rmsd C a b5c:PR-957/b5i:PR-957: 0.55 Å ) ( Figures 4E, 6B , and 6D), covalent modification of b5c is hampered by steric hindrance with Met45, thereby explaining the selectivity of PR-957 for the ChTL activity of the iCP.
Due to comparable sizes of the S1 pockets of b5c and yb5, binding of PR-957 to yb5 is also hindered by Met45 and requires its dislocation ( Figures 7D and S6D) . Nevertheless, the IC 50 value of PR-957 for subunit yb5 is lower than for b5c (Figure 5 ), supporting the assumption that yb5 may represent an intermediate stage between b5c and b5i.
Docking of PR-957 to the Active Site Thr1
Epoxyketones such as the natural product epoxomicin and its structural analog PR-957 have been proposed to react in a two-step mechanism with the N-terminal Thr1 of catalytically active proteasome subunits (Groll et al., 2000) . To analyze the docking of the compound to the active site and to prove the order of reaction steps, we determined the crystal structures of yCPs incubated for varying times with different concentrations of PR-957. We obtained two datasets that clearly capture distinct reaction states of PR-957 with Thr1O g of yb5 (Figures 7A and 7B) and that confirm the formerly proposed mode of action of epoxyketone inhibitors ( Figure 7C ). Following a reversible hemiketal formation of Thr1O g with the ketone group of PR-957 ( Figures 7A and 7C ), the epoxide is nucleophilically attacked by the amine group of Thr1, leading to the formation of a morpholine ring by an irreversible intermolecular cyclization ( Figures 7B and 7C) . Remarkably, in the electron density map representing the hemiketal formation, the intact epoxide of PR-957 and only its P1 site are structurally defined ( Figure 7A ). Even though the P1 Figure 7E ), the first docking of the inhibitor to the active site occurs solely by its reactive functional group and its interactions with the S1 pocket of the active b-subunit. Subsequent contacts with the S2 and S3 sites lead to the formation of an antiparallel b sheet of the peptide moiety in the substrate-binding channel. Despite the importance of all three substrate-specificity pockets for the selectivity of a compound and for its IC 50 value, our complex structures provide evidence that predominantly differences in the S1-binding pocket, in particular the orientation of Met45, are largely responsible for the enhanced affinity of PR-957 for b5i compared to b5c.
DISCUSSION
Our crystallographic data on the cCP and iCP reveal a similar architecture for c-and i-subunits, which is expected from an evolutionary point of view. However, our findings highlight the influence of subtle, yet biologically significant changes that could not have been predicted based on the existing structures of the yCP and bovine cCP. The differences in c-and i-subunits provide an explanation for enhanced antigen processing by iCPs as well as the molecular basis for the b5i selectivity of the inhibitor PR-957 and could be elucidated only by comparison of the six crystal structures reported in this work.
Molecular Differences between the c-and i-Subunits and Their Implications for Antigen Processing
Due to their high structural similarity, both b2c and b2i are able to generate MHC-I epitopes with neutral or basic C-terminal anchor residues (Rammensee et al., 1995) . In addition, as often suggested, the structure of the iCP proves that the b1i substratebinding channel is lined with hydrophobic amino acids, which enhance the production of MHC-I epitopes ending with small, nonpolar residues (Boes et al., 1994; Groll et al., 1997; Orlowski et al., 1993) . Thus, in b1i-deficient mice, the peptide specificity of cytotoxic T cell responses is altered (Chen et al., 2001 ).
Apart from b1i, subunit b5i also enhances the generation of MHC-I ligands . Our data suggest that peptide bond hydrolysis might be favored by an increased hydrophilicity of the active site and additional hydrogen bonds modulating the oxyanion hole. In particular, the presence of the strictly conserved residues Ser46 and Thr127 (Data S1F) might lead to a dominant active site in the iCP, which may explain the outstanding role of subunit b5i in antigen presentation. Indeed, increased processing kinetics were reported to stimulate the immunogenicity of antigens (Deol et al., 2007) , and the activity of the 26S immunoproteasome was shown to be two times higher than that of its constitutive counterpart (Seifert et al., 2010) .
In addition, compared to b5c, the introduction of an S2 pocket in subunit b5i augments its specificity for the P2 site of protein substrates and might influence its cleavage pattern.
However, most striking is the distinct conformation of Met45 in b5i relative to b5c, leading to differently sized S1 pockets. The smaller S1 pocket of b5c predominantly accommodates peptides with tiny hydrophobic amino acids such as Ala or Val. In contrast, the significantly enlarged S1 pocket of b5i leads to a preferential cleavage after large nonpolar residues like Tyr , Trp, and Phe. These observations agree with the specific hydrolysis of the known fluorogenic substrates Ac-WLA-AMC and Ac-ANW-AMC by b5c and b5i, respectively (Blackburn et al., 2010) .
Nonetheless, both ChTL activities display a certain degree of overlapping substrate specificities, especially with respect to Leu, Ile, and Tyr. Ligand docking to the active site reveals that Leu and Ile nicely fit into b5c; however, after initial binding to the S1 site, Met45 still must perform structural rearrangements ( Figures 7E and S4B ). Tyr also induces the dislocation of Met45, but its hydroxyl group can be stabilized in the S1 pocket by Ser53 of subunit b5c and Ser129 of the neighboring subunit b6.
In conclusion, b5i plays a key role in antigen processing by producing a broad variety of MHC-I epitopes ending with a branched or spacious hydrophobic anchor residue (Rammensee et al., 1995) . In accord with our hypotheses, b5i-but not b1i-or b2i-deficient mice show a 50% reduced expression of MHC-I molecules (Basler et al., 2006; Fehling et al., 1994; Groettrup et al., 2010; Van Kaer et al., 1994) and are more susceptible to infectious diseases (Tu et al., 2009) . Moreover, as subunit b5i is involved in cytokine production (Muchamuel et al., 2009) , it may proteolytically activate certain regulatory factors by cleavage after bulky hydrophobic amino acid residues.
The importance of the ChTL activity for antigen presentation is further supported by recent studies on the tCP, which differs from the iCP only by the exchange of subunit b5i with b5t. Lining of the substrate-binding channel of b5t with the hydrophilic side chains Ser20, Ser31, Thr45, and Ser49 reduces the ChTL activity and leads to the production of low-affinity epitopes for MHC-I receptors (Data S1G). This might be crucial for the positive selection of developing T cells in the thymus (Murata et al., 2007; Tomaru et al., 2009; van Endert, 2011) .
Based on the structural similarity of CPs, we attempted to investigate the subtle differences between the subunits b5c and b5i in more detail. By mutation of key amino acids in yb5, we tried to mimic main characteristics of subunit b5i in yeast. However, thus far none of the mutants displays an affinity for PR-957 that is comparable to that of mammalian b5i (E.M.H., M. Groll, W.H., unpublished data). Additionally, exchange of yb5 by the corresponding murine or human i-subunit was lethal to yeast, even after replacement of their genuine propeptides by that of yb5. These observations might reflect the different assembly pathways of the yCP/cCP as well as iCP (Chen and Hochstrasser, 1996; De et al., 2003; Nandi et al., 1997) and the high phylogenetic distance between yeast and mouse. Furthermore, our structural data indicate that the amino acids in proximity to the active site and on the contact surfaces to adjacent subunits form a unique network that is specific for each organism and, thus, cannot be simply transferred between species.
Structural Requirements for Selective iCP Inhibitors
In autoimmune and neurodegenerative diseases, as well as in various types of cancer, the levels of proinflammatory cytokines are elevated resulting in increased iCP expression (Díaz-Herná ndez et al., 2003; Ho et al., 2007; Puttaparthi and Elliott, 2005; Singh et al., 2011; Visekruna et al., 2009) . In several studies, the b5i-specific compound PR-957 has been shown to reduce the level of cytokines and autoantibodies, to modulate cytotoxic T cell responses, and to prevent disease progression in rheumatoid arthritis, experimental colitis, as well as systemic lupus erythematosus Ichikawa et al., 2011; Muchamuel et al., 2009) .
Our crystallographic investigations on PR-957 revealed a binding mechanism common to all active sites of cCP, iCP, and yCP ( Figure 4B ), and thus, its selectivity depends, apart from the reactive warhead, solely on the interactions with the substrate-binding channel. Furthermore, docking of PR-957 was shown to occur via its functional headgroup and the P1 site. This is consistent with the observation that nonpeptidic proteasome inhibitors such as salinosporamide A and omuralide target only the S1 pocket (Groll et al., 1997 (Groll et al., , 2006b ). However, peptidic compounds like PR-957 form an antiparallel b sheet in the substrate-binding channel, indicating that the P2 and P3 sites also contribute to their specificity.
Based on the following structural requirements, inhibitors specific for b1c, b1i, b5c, or b5i can now be developed: the S1 pocket of subunit b1c favors negatively charged residues, whereas the corresponding pocket in b1i accommodates branched nonpolar side chains. Additionally, comparing subunits b1c and b1i, the latter prefers smaller and more polar amino acids in P3. b5c-selective compounds require hydrophobic residues like Leu or less structurally demanding amino acids in P1 and bulky hydrophobic side chains in P3. In contrast, inhibitors specific for subunit b5i need large hydrophobic groups such as Trp or Phe in P1 (Toes et al., 2001 ) and small polar residues in P3.
The phenyl side chain of PR-957 perfectly fits into the spacious S1 pocket of b5i but not into the smaller one of b5c, which explains the subunit specificity of this inhibitor. The forces necessary to enlarge the S1 pocket of b5c by pushing Met45 aside are mirrored in the almost 15 times higher IC 50 value of PR-957 for b5c. Similarly, engineered derivatives of omuralide and salinosporamide A, with a phenyl moiety in P1, have been demonstrated to exert significantly reduced (D) Superposition of the subunits yb5 and b5c, pointing out the structural similarity of both CPs. The side chain Gln53 in yb5, the only sequence difference in the S1 pocket compared to b5c, is marked in magenta. Gly47 and Thr1 are colored in black.
(E) Superposition of PR-957 in its epoxide (ep; yellow) and morpholine (mo; gray) form bound to subunit yb5. Note that during docking, the P1 residue is not yet properly positioned in the S1 pocket (green arrow). A black dashed arrow marks the position where Thr1NH 2 attacks the intact epoxide group, resulting in the irreversible formation of a secondary amine as part of the morpholine ring. See also Figure S6 .
inhibitory potency toward the ChTL activity of yCP and cCP compared to the natural products (Corey and Li, 1999; Nett et al., 2009) . Because salinosporamide A (marizomib) is tested in clinical phase studies (Potts et al., 2011) , it would be interesting to characterize the selectivity of these derivatives for the iCP. Besides PR-957, our structural data provide an explanation for the selectivity of well-characterized proteasome inhibitors (Figure S4A ): As carfilzomib, currently in clinical phase 3 trials (Khan and Stewart, 2011) , and PR-825 harbor Leu side chains in P1 and hydrophobic residues in P3, they both favor subunit b5c over b5i. Whereas the tripeptidic inhibitor PR-825 is >10-fold more selective for b5c, the tetrapeptide carfilzomib displays only slight specificity for b5c (<3-fold), indicating that P2, P3, and P4 residues also significantly influence the degree of selectivity (Kuhn et al., 2007; Muchamuel et al., 2009) .
In contrast, bortezomib targets both ChTL activities to the same extent . Superposition of the murine CPs with the yCP:bortezomib X-ray structure (Groll et al., 2006a) reveals that the N-terminal pyrazole ring of bortezomib can occupy the S3 pocket of both b5c and b5i by interacting with Thr21, Ala22, and Ala27/Ser27 of b5c/i as well as Asp114 of b6 ( Figure S4B ). Based on our crystal structures and with respect to a sequence identity of more than 90% between murine and human proteasomal subunits, the selectivity of bortezomib could now be improved for either iCP or cCP.
In conclusion, the presented crystal structures of cCP and iCP from the same species enable molecular modeling studies with both mammalian proteasome classes for the first time. Using the outline above, it is now possible to undertake the structureguided design of inhibitors that target single proteasomal subunits in order to modulate signaling processes such as antigen presentation or cytokine production, both of which play pivotal roles in various diseases. The ability to visualize the unique characteristics of iCP that evolved to serve immune responses may offer humankind a therapeutic window of opportunity.
EXPERIMENTAL PROCEDURES
Purification of CPs
Murine cCPs were purified from livers of b2i À/À and b5i À/À gene targeted mice as previously described (Schmidtke et al., 2000) . To obtain iCP samples, BALB/c mice were infected intravenously with 200 p.f.u. LCMV-WE leading to an almost complete conversion to iCPs in the liver on day 8 post-infection (Khan et al., 2001) , when organs were removed. Murine iCPs were purified from pooled livers (Schmidtke et al., 2000) . Human cCPs were isolated from erythrocytes (Schmidtke et al., 2000) , and human iCPs were purchased from Enzo Life Sciences. yCPs were isolated applying standard protocols (Groll and Huber, 2005) .
Crystallization and Structure Determination of cCP and iCP cCP and iCP crystals grew from a 1:1 mixture of protein (30 mg/ml) and reservoir solution (iCP: 0.2 M sodium iodide, 40% MPD; cCP: 0.2 M sodium formate, 40% MPD). cCP and iCP crystals were soaked with PR-957 at a final concentration of 3 mM for 8 hr. Structures were solved by molecular replacement using the bovine cCP as a starting model (PDB ID 1IRU) (Unno et al., 2002) and refined according to standard procedures (see Extended Experimental Procedures).
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